Home›Trial›NCT07188558
🔬NCT07188558Phase 3RECRUITING

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Study Summary

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Conditions
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaNon-Hodgkin Lymphoma Refractory/ RelapsedDiffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma Relapsed
Interventions / Drugs
rondecabtagene autoleucelaxicabtagene ciloleucellisocabtagene maraleucel
View on ClinicalTrials.gov ↗
Sponsor
LYEL
Lyell Immunopharma
Cell Therapy
D38/100
Study Details
Enrollment400 participants
Primary Completion—
Lead SponsorLyell Immunopharma, Inc.
Data Retrieved2026-04-11 04:20:24.455767+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.